Validity of simplified 3′-Deoxy-3′-[18F] fluorothymidine uptake measures for monitoring response to chemotherapy in locally advanced breast cancer

Molecular Imaging and Biology

Volumn 14, Issue 6, 2012, Pages 777-782

  Lubberink, Mark ^a,b,e   Direcks, Wieteke ^a   Emmering, Jasper ^a   Van Tinteren, Harm ^d   Hoekstra, Otto S ^a   Van Der Hoeven, Jacobus J ^c   Molthoff, Carla F M ^a   Lammertsma, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

^c Location Alkmaar   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

FLT; Modelling; PET; Response monitoring; SUV

Indexed keywords

3' FLUOROTHYMIDINE F 18; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG RESPONSE; DRUG UPTAKE; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME; VALIDATION STUDY;

BREAST NEOPLASMS; DIDEOXYNUCLEOSIDES; FEMALE; HUMANS; NEOPLASM STAGING; NONLINEAR DYNAMICS; REGRESSION ANALYSIS; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 84870461025     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0547-1     Document Type: Article

References (21)

1. Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334-1336
2. Vesselle H, Grierson J, Muzi M et al (2002) In vivo validation of 3′ deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8:3315-3323
3. Brockenbrough JS, Souquet T, Morihara JK et al (2011) Tumor 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of 18F-FLT PET studies in lung tumors. J Nucl Med 52:1181-1188
4. Krak NC, Hoekstra OS, Lammertsma AA (2004) Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. Eur J Nucl Med Mol Imaging 31(Suppl 1):S103-S111
5. Visvikis D, Francis D, Mulligan R et al (2004) Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging 31:169-178
6. Shields AF, Lawhorn-Crews JM, Briston DA et al (2008) Analysis and reproducibility of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res 14:4463-4468
7. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA (2005) Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 46:371-380
8. Muzi M, Vesselle H, Grierson JR et al (2005) Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 46:274-282
9. Hoekstra CJ, Paglianiti I, Hoekstra OS et al (2000) Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 27:731-743
10. Krak NC, van der Hoeven JJ, Hoekstra OS, Twisk JW, van der WE, Lammertsma AA (2003) Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur J Nucl Med Mol Imaging 30:674-681
11. Kenny LM, Vigushin DM, Al-Nahhas A et al (2005) Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 65:10104-10112
12. Patlak CS, Blasberg RG (1985) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5:584-590
13. Schiepers C, Dahlbom M, Chen W et al (2010) Kinetics of 3′-deoxy-3′-18F-fluorothymidine during treatment monitoring of recurrent highgrade glioma. J Nucl Med 51:720-727
14. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34:1339-1347
15. Cheebsumon P, Velasquez LM, Hoekstra CJ et al (2011) Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging 38:832-842
16. Lubberink M, Boellaard R, van der Weerdt AP, Visser FC, Lammertsma AA (2004) Quantitative comparison of analytic and iterative reconstruction methods in 2-and 3-dimensional dynamic cardiac 18F-FDG PET. J Nucl Med 45:2008-2015
17. van der Weerdt AP, Klein LJ, Boellaard R, Visser CA, Visser FC, Lammertsma AA (2001) Image-derived input functions for determination of MRGlu in cardiac (18)F-FDG PET scans. J Nucl Med 42:1622-1629
18. Gunn RN, Sargent PA, Bench CJ et al (1998) Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-C-11]WAY-100635 for PET. Neuroimage 8:426-440
19. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Autom Control 19:716-723
20. de Langen AJ, Klabbers B, Lubberink M et al (2009) Reproducibility of quantitative (18)F-3′-deoxy-3′-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 36:389-395
21. Shields AF, Briston DA, Chandupatla S et al (2005) A simplified analysis of [18F]3′-deoxy-3′-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging 32:1269-1275